# Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia

> **NCT01005576** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 21 (actual)

## Conditions studied

- Severe Thalassemia

## Interventions

- **DRUG:** Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan

## Key facts

- **NCT ID:** NCT01005576
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2014-04
- **Final completion:** 2014-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-12-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01005576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01005576, "Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01005576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*